MilliporeSigma has announced a substantial $76 million investment to expand its Bioconjugation Center of Excellence in St. Louis, Missouri, aiming to triple its current capacity for Antibody-Drug Conjugates (ADCs). This significant expansion will encompass upgrading 34,000 square feet of existing space, including the addition of new laboratories, a dedicated buffer preparation facility, and enhanced storage capabilities. The move is intended to bolster the company’s contract development and manufacturing organization (CDMO) services, which support the development of both early-stage and commercial bioconjugates. By increasing its capacity, MilliporeSigma aims to accelerate the market entry of innovative therapies that could transform cancer treatment.
ADCs represent a significant advancement in targeted cancer treatments, offering a way to deliver potent cancer-fighting agents directly to cancer cells, thus reducing damage to healthy tissues. This targeted approach has the potential to minimize the need for more invasive treatments such as chemotherapy and radiation, which often come with debilitating side effects. With over 35 years of experience in ADC manufacturing, MilliporeSigma is well-positioned to lead in this transformative oncology field, ensuring that these groundbreaking therapies reach patients more quickly and effectively.
Broader Implications of Expansion
MilliporeSigma is making a major $76 million investment to expand its Bioconjugation Center of Excellence in St. Louis, Missouri. This expansion aims to triple its current capacity for producing Antibody-Drug Conjugates (ADCs). The project includes upgrading 34,000 square feet of current space to add new labs, a buffer preparation facility, and better storage. This upgrade is designed to boost the company’s contract development and manufacturing services, which focus on early-stage and commercial bioconjugates. By increasing capacity, MilliporeSigma hopes to speed up the availability of innovative therapies that could revolutionize cancer treatment.
ADCs are a major advancement in targeted cancer therapy, enabling the delivery of powerful cancer-fighting agents directly to cancer cells while minimizing harm to healthy tissues. This targeted method can lessen the need for invasive treatments like chemotherapy and radiation, which often have severe side effects. With over 35 years of experience in ADC manufacturing, MilliporeSigma is in an excellent position to lead in this cutting-edge field of oncology, ensuring that these promising therapies reach patients quicker and more effectively.
